Pharmaceuticals
Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment
* Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for osteoporosis and cancer-related bone loss more affordable for millions of Thais * This approval builds on Abbott's biosimilar portfolio in Asia Pacific, following recent launches inMalaysia and Indi...
2025-08-26 14:29
3074
Basecare Medical (02170.HK) Gems Culture Medium Receives First Approval from NMPA, Advancing the Localization of Assisted Reproductive Fluids
SUZHOU, China, Aug. 26, 2025 /PRNewswire/ -- Recently, Suzhou Basecare Medical Co., Ltd. achieved a major breakthrough—its globally leading Gems culture medium (embryo handling solution VitBase) has officially received registration approval from the National Medical Products Administration (NMPA)...
2025-08-26 11:47
4154
Neopharma Technologies and Orient Gene Partner to Digitize Healgen® Drug Test Portfolio Globally with NEOVAULT®
Partnership delivers tamper-evident, high-integrity testing data aligned with U.S. Drug Policy Priorities WASHINGTON, Aug. 26, 2025 /PRNewswire/ -- Neopharma Technologies Limited ("Neopharma") today announced it hasentered into a global software licensing and collaboration agreement with Zhejian...
2025-08-26 02:10
2650
Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach
SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2025 interim results. In the first half of 2025, Henlius' revenue reached about RMB2.8195 billion, representing an increase of 2.7% YoY. The gross profit of RMB2.1992 billion, up by 10.5% YoY, with a net profit reached RMB390....
2025-08-25 21:18
5018
Everest Medicines Announces Participation in September Investor Conferences
SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced thatIan Woo, President and Chief Fin...
2025-08-25 20:57
2477
Acceleration in Clinical Development! Leads Biolabs' LBL-034 Dosed First Patient in Phase Ⅱ Trial
NANJING, China, Aug. 25, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following strong Phase Ⅰ data.This milestone endows...
2025-08-25 18:27
3965
Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer
SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), today announced the appointment ofFrancis Duhay, MD, MBA, FACS as Global Chief Medical Officer. Dr. Duhay, a board-certified General and ...
2025-08-25 16:42
3664
Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy
* The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at the International Epilepsy Annual Congress1 * DEEs ar...
2025-08-25 15:43
1860
Cambrex Expands Peptide Manufacturing Capabilities in Waltham, Massachusetts
EAST RUTHERFORD, N.J., Aug. 25, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has expanded its active pharmaceutical ingredient (API) facility inWaltham, Massachusetts to fur...
2025-08-25 12:01
2989
Antengene Announces 2025 Interim Financial Results Highlighting Encouraging Data from Mid/Late-Stage Clinical Programs and Its Innovative TCE Technology Platform
* The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a favorable safety profile in patients with gastric/gastroesophageal junction adenocarcinoma across high, low, and ultra-low CLDN18.2 expression level...
2025-08-22 18:14
3429
MALAYSIA SHOWCASES HEALTHCARE EXCELLENCE IN CAMBODIA, DRIVING MOMENTUM TOWARDS MYMT 2026
KUALA LUMPUR, Malaysia, Aug. 22, 2025 /PRNewswire/ -- The Malaysia Healthcare Travel Council (MHTC) proudly presents Malaysia Healthcare Week 2025 inPhnom Penh, Cambodia, an initiative designed to strengthening healthcare ties between the two nations and positionMalaysia as the medical tourism de...
2025-08-22 11:00
3591
Biosyngen Unveils Innovative Strategies for Next-Generation TIL Therapies in Asia Bio 2025 Singapore
SINGAPORE, Aug. 22, 2025 /PRNewswire/ -- Asia Bio Innovation Summit 2025 is one of the premier industry-focused events inAsia and focus on the hottest topics of ADC and CGT. Asia Bio Innovation summit 2025 Singapore brought together 30+ world-class Speakers, 10+ Exhibitors and 200+ Attendees from...
2025-08-22 09:55
4523
Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results
Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic soralimixin Strong Cash Position to Pursue New Discovery Opportunities and Partnership Strategy Conference Calls Scheduled: Eng...
2025-08-21 18:02
9049
Debut of new form of health supplement product! WCC biomedical collaborate with Synmosa toward the niche market!
TAIPEI, Aug. 21, 2025 /PRNewswire/ -- WCC Biomedical
2025-08-21 09:23
2266
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth
MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended30 June 2025. All figures are in USD unless stated otherwise. H1 2025 key results[1] Group performan...
2025-08-21 08:23
3574
XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies
CAMBRIDGE, Mass., Aug. 20, 2025 /PRNewswire/ -- XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases. This collaboration will be based o...
2025-08-20 08:00
4545
Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC
CHENGDU, China, Aug. 19, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in combination with PD-L1 monocl...
2025-08-19 20:09
2425
Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma
SHANGHAI and HONG KONG, Aug. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic ma...
2025-08-19 13:26
2784
Beyfortus® (nirsevimab) approved in Singapore to protect all infants against RSV disease
* Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public health impact demonstrated in the real world.[1] * In the recent HARMONIE trial findings, Beyfortus reduced RSV hospitalisation...
2025-08-19 11:00
3656
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
YANTAI, China, Aug. 19, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned subsidiary o...
2025-08-19 08:00
3282
Week's Top Stories
Most Reposted
DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 277 media titles]
2026-10-06 05:28SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 276 media titles]
2026-10-07 11:50Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 271 media titles]
2026-10-01 10:00
Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines
[Picked up by 263 media titles]
2026-10-02 16:27
Southeast Asia's China travel map is widening, Traveloka platform data shows
[Picked up by 262 media titles]
2026-10-05 11:51Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
23942